Lakewood-Amedex Biotherapeutics Inc. (LABT) — IPO Analysis
By Kian O Connor | Updated 4/29/2026
Company Overview
Performance Overview
Since going public at $3.66 per share on Apr 23, 2026, Lakewood-Amedex Biotherapeutics Inc. shares have gained 6.3%, rewarding investors who participated in the IPO. The stock currently trades at $3.89, giving the company a market capitalization of $54.5M.
Lockup Expiration
The lockup period for Lakewood-Amedex Biotherapeutics Inc. insiders is set to expire on Oct 20, 2026, which is 174 days from now. When the lockup expires, insiders and early investors who received shares before the IPO will be free to sell their holdings on the open market. This can create significant selling pressure and is closely watched by traders and institutional investors alike.
Industry Context
Lakewood-Amedex Biotherapeutics Inc. operates in the Pharmaceutical Preparations sector, which has seen varied IPO activity in recent years. The company is headquartered in FL and is classified under SIC code 2834. Understanding the competitive landscape and sector dynamics is essential for evaluating the long-term prospects of any newly public company in this space. Investors should consider broader market conditions, sector-specific trends, and company fundamentals when assessing LABT as an investment.
Trading History
Lakewood-Amedex Biotherapeutics Inc. is actively trading in the public markets with a current share price of $3.89. The company went public at $3.66 per share, resulting in gains of 6.3% for IPO investors. With a current market capitalization of $54.5M, Lakewood-Amedex Biotherapeutics Inc. continues to establish its presence as a publicly traded entity in the Pharmaceutical Preparations.
Important Disclaimer
This analysis of Lakewood-Amedex Biotherapeutics Inc. (LABT) is provided for informational purposes only and should not be construed as investment advice. All data is sourced from SEC EDGAR filings and public market feeds. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. IPOLockup.io is an independent research platform with no financial interest in any of the companies covered.